One Year Follow-Up of Children and Adolescents With Chronic Immune Thrombocytopenic Purpura (ITP) Treated With Rituximab

被引:41
作者
Mueller, Brigitta U. [2 ,3 ]
Bennett, Carolyn M. [1 ,4 ]
Feldman, Henry A. [4 ,5 ]
Bussel, James B. [6 ]
Abshire, Thomas C. [7 ]
Moore, Theodore B. [8 ]
Sawaf, Hadi [9 ]
Loh, Mignon L. [10 ]
Rogers, Zora R. [11 ]
Glader, Bertil E. [12 ]
McCarthy, Maggie C. [4 ,5 ]
Mahoney, Donald H. [2 ,3 ]
Olson, Thomas A. [7 ]
Feig, Stephen A. [8 ]
Lorenzana, Adonis N. [9 ]
Mentzer, William C. [10 ]
Buchanan, George R. [11 ]
Neufeld, Ellis J. [1 ]
机构
[1] Childrens Hosp, Div Hematol Oncol, Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Baylor Coll Med, Hematol Serv, Houston, TX 77030 USA
[3] Baylor Coll Med, Texas Childrens Canc Ctr, Houston, TX 77030 USA
[4] Harvard Univ, Sch Med, Boston, MA USA
[5] Childrens Hosp, Clin Res Program, Boston, MA 02115 USA
[6] Cornell Univ, Dept Pediat, Weill Med Coll, New York, NY 10021 USA
[7] Emory Univ, Sch Med, Atlanta, GA USA
[8] Univ Calif Los Angeles, Mattel Childrens Hosp, Los Angeles, CA USA
[9] St Johns Hosp, Van Eslander Canc Ctr, Detroit, MI USA
[10] Univ Calif San Francisco, San Francisco, CA 94143 USA
[11] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA
[12] Stanford Univ, Stanford, CA 94305 USA
关键词
clinical trial; immune thrombocytopenia; rituximab; ANTI-CD20; MONOCLONAL-ANTIBODY; INTRAVENOUS GAMMA-GLOBULIN; CHILDHOOD; EFFICACY; ADULTS;
D O I
10.1002/pbc.21757
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. We previously showed in a prospective Study that rituximab appears to be effective in some children and adolescents with severe chronic immune thrombocytopenia. Eleven of 36 patients achieved and maintained platelet counts Over 50,000/mm(3) within the first 12 weeks. These patients were followed for the next year. Methods. Platelet Count,; were monitored monthly and all subsequent bleeding manifestations and need for further treatment was noted. Results. Eight of the 11 initial responders maintained a platelet count over 150,000/mm(3) Without further treatment intervention. Three patients had a late relapse. One initial non-responder achieved a remission after 16 weeks, and two additional patients maintained platelet counts around 50,000/mm(3) without the need for further intervention. Conclusions. Rituximab resulted in sustained efficacy with platelet Counts of 50,000/mm(3) or higher in 11 of 36 patients (31%). Pediatr Blood Cancer 2009;52:259-262. (C) 2008 Wiley-Liss, Inc.
引用
收藏
页码:259 / 262
页数:4
相关论文
共 18 条
[1]   INTRAVENOUS GAMMA-GLOBULIN IN REFRACTORY IMMUNE THROMBOCYTOPENIC PURPURA - EFFICACY WITH OR WITHOUT CONCOMITANT STEROID-THERAPY [J].
ABRAMS, RA ;
ASTER, R ;
ANDERSON, T .
AMERICAN JOURNAL OF HEMATOLOGY, 1985, 18 (01) :85-89
[2]  
Aggarwal A, 2002, SOUTHERN MED J, V95, P1209
[3]   Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura [J].
Bennett, CM ;
Rogers, ZR ;
Kinnamon, DD ;
Bussel, JB ;
Mahoney, DH ;
Abshire, TC ;
Sawaf, H ;
Moore, TB ;
Loh, ML ;
Glader, BE ;
McCarthy, MC ;
Mueller, BU ;
Olson, TA ;
Lorenzana, AN ;
Mentzer, WC ;
Buchanan, GR ;
Feldman, HA ;
Neufeld, EJ .
BLOOD, 2006, 107 (07) :2639-2642
[4]  
Blanchette V, 2008, PEDIATR CLIN N AM, V55, pix
[5]   Childhood immune thrombocytopenic purpura: Diagnosis and management [J].
Blanchette, Victor ;
Bolton-Maggs, Paula .
PEDIATRIC CLINICS OF NORTH AMERICA, 2008, 55 (02) :393-+
[6]   Grading of hemorrhage in children with idiopathic thrombocytopenic purpura [J].
Buchanan, GR ;
Adix, L .
JOURNAL OF PEDIATRICS, 2002, 141 (05) :683-688
[7]  
BUSSEL JB, 1991, BLOOD, V77, P1884
[8]  
Coiffier B, 1998, BLOOD, V92, P1927
[9]   The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura [J].
Cooper, N ;
Stasi, R ;
Cunningham-Rundles, SS ;
Feuerstein, MA ;
Leonard, JP ;
Amadori, S ;
Bussel, JB .
BRITISH JOURNAL OF HAEMATOLOGY, 2004, 125 (02) :232-239
[10]   Rituximab for adolescents with haemophilia and high titre inhibitors [J].
Fox, RA ;
Neufeld, EJ ;
Bennett, CM .
HAEMOPHILIA, 2006, 12 (03) :218-222